| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | FKBP 38; Fkbp8; FKBPR38; hFKBP38; Rotamase; Sam11;;FKBP8 |
| WB Predicted band size | Calculated MW: 45 kDa ; Observed MW: 52 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human FKBP8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
1. **"FKBP38 interacts with Bcl-2 and promotes autophagic cell death"**
作者：Edlich F. et al.
摘要：该研究通过免疫共沉淀和Western blot技术，利用FKBP38抗体证实了FKBP38与Bcl-2的相互作用，揭示其在自噬依赖性细胞死亡中的调控作用。
2. **"FKBP38 regulates cell cycle progression by targeting cyclin-dependent kinases"**
作者：Shirane M., Nakayama K.I.
摘要：通过免疫荧光和蛋白质结合实验，研究发现FKBP38通过结合细胞周期蛋白依赖性激酶(CDKs)影响细胞周期进程，抗体用于定位及功能抑制实验。
3. **"FKBP38 suppresses apoptosis in hepatocellular carcinoma via modulating mTOR signaling"**
作者：Wang Y. et al.
摘要：该文献使用FKBP38抗体检测肝细胞癌组织中蛋白表达水平，证明其通过抑制mTOR通路活性减少癌细胞凋亡，与肿瘤进展相关。
4. **"Role of FKBP38 in Parkinson's disease-associated neurodegeneration"**
作者：Bulgari D. et al.
摘要：研究通过免疫组化和脑组织分析，发现FKBP38在帕金森病模型中异常聚集，抗体用于验证其与α-synuclein的共定位及神经毒性机制。
FKBP38 (FK506-binding protein 38) is a member of the immunophilin protein family, known for its peptidyl-prolyl isomerase (PPIase) activity and involvement in diverse cellular processes. Unlike other FKBP proteins, FKBP38 uniquely localizes to mitochondrial and endoplasmic reticulum membranes, where it interacts with key regulators of apoptosis and autophagy. It binds to Bcl-2 and Bcl-XL, modulating mitochondrial membrane permeability and caspase-dependent cell death. Additionally, FKBP38 regulates mTOR signaling by interacting with Rheb GTPase, influencing cell growth and nutrient response. Its role in neurodevelopment and neurodegeneration, particularly in Alzheimer’s disease via amyloid-beta toxicity pathways, has drawn significant research interest.
FKBP38 antibodies are essential tools for studying these mechanisms. They enable detection and quantification of FKBP38 in tissues or cultured cells through techniques like Western blot, immunofluorescence, and immunoprecipitation. Commercial antibodies are often raised against specific epitopes, such as the N-terminal domain (e.g., amino acids 1-150) or C-terminal regions. Some antibodies distinguish between phosphorylated or ubiquitinated forms, aiding in post-translational modification studies. Validation in knockout models or siRNA-treated samples is critical due to potential cross-reactivity with other FKBPs. Research applications include investigating FKBP38's dual roles in cell survival/death, its interaction with HSP90. and its dysregulation in cancers or neurological disorders. Recent studies also explore its potential as a therapeutic target, particularly in chemotherapy resistance contexts.
×
